Exponent (EXPO) Q4 2024 earnings summary

Executive summary

• Fourth quarter and fiscal year 2024 results exceeded expectations, with mid-single digit net revenue growth, improved utilization, and EBITDA margin, reflecting business resilience and effective resource management.

• Growth was driven by proactive services in consumer electronics and utilities, and reactive services in utilities and medical devices, with chemicals industry activity rebounding in Q4.

• The company is positioned to support clients amid technological transformation and regulatory complexity, especially in digital health, energy, and chemicals.

• The company remains focused on aligning resources with demand and is well-positioned for continued growth amid industry disruptions.

Financial highlights

• Q4 2024 total revenues rose 11.3% to $136.8M (14 weeks); net revenues up 9% to $123.8M, aided by an extra week.

• Q4 net income was $23.6M ($0.46/diluted share), up from $20.9M ($0.41/diluted share) year-over-year; consolidated tax rate dropped to 24.7% from 30.4%.

• Fiscal 2024 revenues increased 4.1% to $558.5M (53 weeks); net income rose 9% to $109M ($2.11/diluted share).

• Q4 EBITDA was $31.2M (25.2% margin); full-year EBITDA reached $147.1M (28.4% margin), up 70 basis points year-over-year.

• Year-end cash and equivalents: $258.9M; $58.3M paid in dividends during 2024.

Outlook and guidance

• Q1 2025 net revenues expected to decline low single digits year-over-year due to a 5%-6% headcount deficit; EBITDA margin guidance of 25.0%-26.0%.

• Full-year 2025 net revenues projected to grow in the low single digits; EBITDA margin expected at 26.25%-27%.

• Sequential headcount growth of 1%-2% per quarter anticipated, with year-end headcount at least 4% above the start; 2025 will revert to a 52-week fiscal year, creating a comparison headwind.

• Utilization for 2025 expected at 72%-73%; realized rate increase of 3%-3.5%.

• Capital expenditures for 2025 forecasted at $10M-$12M.